Skip to main content

Table 1 Baseline characteristics of studies in MDR or XDRP.aeruginosa

From: Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Author, Year Design Country Case/Exposure Control/Comparator Total N Age cases (Yr) Age control (Yr) Male cases (%) Male control (%)
Aloush, 2006 [12] CC, matched Israel MDR P. aeruginosa Patients with MDR P. aeruginosa 164 65 63 60 50
Bodro, 2015 [13] P, cohort Spain XDR P. aeruginosa Other pathogens 318 Median: 59 Median: 62 77.4 69.7
Cao, 2004 [14] CC, unmatched China MDR P. aeruginosa P.aeruginosa 112 60 50 59 58.8
Cilloniz, 2016 [15] P, cohort Spain MDR P. aeruginosa Non-MDR P. aeruginosa (not fully described) 68 72.7 71.1 90.9 78.3
Cobos-Trigueros, 2015 [16] P, cohort Spain MDR P. aeruginosa Susceptible or resistant P.aeruginosa and non-P.aeruginosa 850 NR NR NR NR
D’Agata (b), 2006 [17] CC, matched USA, Italy MDR P. aeruginosa Non-P.aeruginosa 302 58 62 62 50
Dalfino, 2011 [18] P, cohort NR MDR P. aeruginosa NR 251 63 63 65 61.3
Dantas, 2014 [19] R, cohort Brazil MDR P. aeruginosa Resistant or susceptible P. aeruginosa 120 51.5 (total) 51.5 (total) 63.3 (total) 63.3 (total)
Defez (a), 2004 [20] CC, matched France MDR P. aeruginosa, nosocomial Hospitalized, non-nosocomial MDRP. aeruginosa 320 73.2 67 56.25 52.5
Defez (b), 2004 [20] CC, unmatched France MDR P. aeruginosa Non MDR- P. aeruginosa (not described) 395 (155) 73.2 NR 56.25 56
Gomez-Zorilla, 2014 [21] P, cohort Spain MDR P. aeruginosa (MDR non-XDR and XDR) Non-MDR P. aeruginosa (not fully described) 112 65.3 (total) 65.3 (total) 69 (total) 69 (total)
Johnson, 2009 [22] R, cohort USA MDR P. aeruginosa Non-MDR P.aeruginosa (not described) 503 median: 59 (total) median: 59 (total) 57 (total) 57 (total)
Joo, 2011 [23] P, cohort South Korea MDR P. aeruginosa Resistant or susceptible P. aeruginosa 202 55 (total) 55 (total) 62.9 (total) 62.9 (total)
Liew, 2013 [24] CC, matched Singapore XDR P. aeruginosa Non-P. aeruginosa or other gram-negative 79 Median: 47 (total) NR 62 (total) NR
Lodise, 2007 [25] CC, unmatched USA MDR P. aeruginosa Non-MDR P.aeruginosa(not fully described)a 351 60.5 (total) 60.5 (total) 61.2 (total) 61.2 (total)
Micek, 2015 [26] R, cohort USA, France, Germany, Italy, Spain MDR P. aeruginosa Non-MDR P. aeruginosa (not fully described) 740 53.5 62.1 62.8 70.2
Montero (a), 2010 [27] CC, unmatched NR MDR P. aeruginosa Non-P. aeruginosa 1035 67.8 67.5 72.5 54.3
Montero (b), 2010 [27] CC, unmatched NR MDR P. aeruginosa Susceptible P.aeruginosa 877 67.8 69.1 72.5 59.4
Nakamura, 2013 [28] P, cohort Japan MDR P. aeruginosa Non MDR P.aeruginosa (not fully described)c 435 NR NR NR NR
Nseir, 2011 [29] P, cohort France MDR P. aeruginosa Non MDR P. aeruginosa (not fully described) 511 60 55 65 69
Ohmagari, 2005 [30] CC, unmatched USA Patients with cancer with MDR P. aeruginosa infection Patients with cancer with susceptible P. aeruginosa infection 54 51.8 60.3 50 58.3
Paramythiotou, 2004 [31] CC, matched France MDR P. aeruginosa Non-P. aeruginosa 68 59 61.5 65 65
Park, 2011 [32] CC, matched South Korea XDR P. aeruginosa Non-XDR P.aeruginosa (not fully described)b 99 65 56 79 46
Pena, 2009 [39] P, cohort Spain MDR P. aeruginosa CRPA 246 67 65 67 67
Pena (a), 2012 [33] R, cohort Spain XDR P. aeruginosa Susceptible P. aeruginosa 138 64.7 65.06 86 70.5
Pena (b), 2012 [33] R, cohort Spain Non-XDR MDR P. aeruginosa Susceptible P. aeruginosa 108 64.85 65.06 54 70.5
Samonis, 2014 [34] R, cohort Greece XDR P. aeruginosa Non-XDR P. aeruginosa (MDR and PDR and sensitive) 89 73 69 81.8 57.3
Tumbarello, 2011 [35] CC, unmatched Italy MDR P. aeruginosa Non-P. aeruginosa 252 62 63 57.5 57.5
Tuncer, 2012 [36] CC, unmatched Turkey MDR and XDR P. aeruginosa Non-MDR P.aeruginosa (not fully described) 120 58.6 58.2 54.1 49.4
Ustun, 2016 [37] CC, unmatched Turkey MDR P. aeruginosa Non-P. aeruginosa 225 29.8 37.9 58.7 65.3
Willmann, 2014 [38] CC, matched Germany XDR P. aeruginosa Non-XDR P. aeruginosa (not fully described) or non- P. aeruginosa 31 56 60 65 78.5
  1. CC Case-control, CRPA carbapenem-resistant P. aeruginosa, MDR multi-drug resistant, P Parallel, PDR Pan-Drug-Resistant, R Retrospective, XDR extremely drug-resistant, YR Year
  2. aLodise 2007: Non-MDR P.aeruginosa = ≥90% for only amikacin, cefepime, and piperacillin-tazobactam
  3. bPark,Y.S 2011:used random selection of controls
  4. cNakamura 2013:Non-MDR defines patients with P. aeruginosa other than the MDR phenotype on the same ward as those with the MDR phenotype within the same month